MCID: CRN027
MIFTS: 47

Corneal Neovascularization

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Corneal Neovascularization

MalaCards integrated aliases for Corneal Neovascularization:

Name: Corneal Neovascularization 12 54 43 15 17 71 32

Classifications:



External Ids:

Disease Ontology 12 DOID:11382
ICD9CM 34 370.6
MeSH 43 D016510
SNOMED-CT 67 19161004
ICD10 32 H16.4
UMLS 71 C0085109

Summaries for Corneal Neovascularization

MalaCards based summary : Corneal Neovascularization is related to keratitis, hereditary and corneal edema. An important gene associated with Corneal Neovascularization is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Angiogenesis Inhibitors and Antineoplastic Agents, Immunological have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and t cells, and related phenotypes are cardiovascular system and hematopoietic system

Wikipedia : 74 Corneal neovascularization (CNV) is the in-growth of new blood vessels from the pericorneal plexus into... more...

Related Diseases for Corneal Neovascularization

Diseases related to Corneal Neovascularization via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 226)
# Related Disease Score Top Affiliating Genes
1 keratitis, hereditary 31.3 VEGFA IL1B FGF2 CRYAA
2 corneal edema 31.2 VEGFA TEK IL1B
3 corneal disease 30.6 VEGFA PECAM1 IL1B FGF2 CRYAA
4 diabetic macular edema 30.2 VEGFA TEK SERPINF1 FLT1 FGF2
5 ischemia 30.1 VEGFA TEK KDR FGF2 CXCL12
6 macular retinal edema 30.0 VEGFA SERPINF1 KDR IL1B FLT1 CRYAA
7 eye disease 29.9 VEGFA SERPINF1 KDR IL1B FLT1 FGF2
8 uveitis 29.9 SERPINF1 IL1B CXCL10 CRYAA
9 neovascular glaucoma 29.8 VEGFA PLG KDR FLT1 FGF2 CRYAA
10 kuhnt-junius degeneration 29.7 VEGFA TEK PLG KDR FLT1 CRYAA
11 hemangioma 29.7 VEGFA TEK PECAM1 KDR FLT1 FGF2
12 vitreoretinopathy, neovascular inflammatory 29.7 VEGFA TIMP2 THBS1 FGF2 CRYAA
13 myopia 29.5 VEGFA TIMP2 SERPINF1 MIR184 FGF2 CRYAA
14 glioblastoma multiforme 29.5 VEGFA PECAM1 KDR IL1B FLT1 CXCL12
15 vascular disease 29.5 VEGFA TEK PLG PECAM1 KDR FGF2
16 retinal vascular disease 29.1 VEGFA TEK SERPINF1 PLG KDR IL1B
17 microvascular complications of diabetes 5 29.0 VEGFA THBS1 TEK SERPINF1 PLG KDR
18 macular degeneration, age-related, 1 28.9 VEGFA THBS1 TEK SERPINF1 PLG PECAM1
19 warburg-cinotti syndrome 11.4
20 septate uterus 10.6 KDR FLT1
21 familial glomangioma 10.6 TEK FGF2
22 angiokeratoma of mibelli 10.5 KDR FLT1
23 microcystic meningioma 10.5 VEGFA FLT1
24 yemenite deaf-blind hypopigmentation syndrome 10.5
25 epithelioid hemangioendothelioma 10.5 VEGFA KDR FLT1
26 primary cutaneous b-cell lymphoma 10.5 VEGFA KDR FLT1
27 arteriovenous malformation 10.5 VEGFA TEK IL1B
28 central retinal vein occlusion 10.5 VEGFA SERPINF1 PLG
29 eales disease 10.5 VEGFA SERPINF1 IL1B
30 lung non-squamous non-small cell carcinoma 10.5 VEGFA KDR FLT1
31 rubeosis iridis 10.5 VEGFA PLG
32 subacute thyroiditis 10.4 VEGFA IL1B FGF2
33 poems syndrome 10.4 VEGFA IL1B FGF2
34 hantavirus pulmonary syndrome 10.4 VEGFA ROBO4 KDR
35 background diabetic retinopathy 10.4 VEGFA KDR IL1B
36 hepatic veno-occlusive disease 10.4 VEGFA PLG FGF2
37 prostate angiosarcoma 10.4 VEGFA PECAM1
38 ischemic bone disease 10.4 VEGFA IL1B FGF2
39 intermittent claudication 10.4 VEGFA TEK FGF2
40 ovarian hyperstimulation syndrome 10.4 VEGFA KDR FLT1
41 vein disease 10.4 VEGFA PLG KDR
42 central nervous system hemangioma 10.4 VEGFA PECAM1
43 placenta accreta 10.4 TEK KDR FLT1
44 glomangioma 10.4 TEK PECAM1
45 gastric ulcer 10.4 VEGFA IL1B FGF2
46 lipodermatosclerosis 10.4 VEGFA TIMP2 FLT1
47 keratopathy 10.4
48 bursitis 10.4 KDR IL1B CXCL12
49 pediatric angiosarcoma 10.4 VEGFA PECAM1
50 exanthem 10.4 VEGFA KDR IL1B

Graphical network of the top 20 diseases related to Corneal Neovascularization:



Diseases related to Corneal Neovascularization

Symptoms & Phenotypes for Corneal Neovascularization

MGI Mouse Phenotypes related to Corneal Neovascularization:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.39 CXCL10 CXCL12 DDR2 FGF2 FLT1 IL1B
2 hematopoietic system MP:0005397 10.22 CXCL10 CXCL12 FGF2 FLT1 IL1B KDR
3 cellular MP:0005384 10.21 CXCL10 CXCL12 DDR2 FGF2 FLT1 KDR
4 homeostasis/metabolism MP:0005376 10.21 CXCL10 DDR2 FGF2 FLT1 IL1B KDR
5 mortality/aging MP:0010768 10.07 CXCL10 CXCL12 DDR2 FGF2 FLT1 IL1B
6 immune system MP:0005387 10.06 CXCL10 CXCL12 FLT1 IL1B KDR PECAM1
7 muscle MP:0005369 9.85 CXCL12 DDR2 FGF2 FLT1 KDR PECAM1
8 nervous system MP:0003631 9.8 CXCL10 CXCL12 DDR2 FGF2 FLT1 IL1B
9 vision/eye MP:0005391 9.28 DDR2 FGF2 FLT1 KDR PLG SERPINF1

Drugs & Therapeutics for Corneal Neovascularization

Drugs for Corneal Neovascularization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Angiogenesis Inhibitors Phase 4
2 Antineoplastic Agents, Immunological Phase 4
3 Immunoglobulins Phase 4
4 Antibodies Phase 4
5 Antibodies, Monoclonal Phase 4
6 Anesthetics Phase 4
7
Doxycycline Approved, Investigational, Vet_approved Phase 2, Phase 3 564-25-0 54671203
8
Oxytetracycline Approved, Investigational, Vet_approved Phase 2, Phase 3 79-57-2 54715139 5280972
9
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
10 Antiparasitic Agents Phase 2, Phase 3
11 Antiprotozoal Agents Phase 2, Phase 3
12 Anti-Infective Agents Phase 2, Phase 3
13 Antimalarials Phase 2, Phase 3
14 Mitogens Phase 2, Phase 3
15 Endothelial Growth Factors Phase 2, Phase 3
16 triamcinolone acetonide Phase 2, Phase 3
17 Triamcinolone diacetate Phase 2, Phase 3
18 Triamcinolone hexacetonide Phase 2, Phase 3
19
Bevacizumab Approved, Investigational Phase 2 216974-75-3
20 Laxatives Phase 1, Phase 2
21 Cathartics Phase 1, Phase 2
22 Carboxymethylcellulose Sodium Phase 1, Phase 2
23 Ophthalmic Solutions Phase 1, Phase 2
24 Interleukin 1 Receptor Antagonist Protein Phase 1, Phase 2
25
Ranibizumab Approved Phase 1 347396-82-1 459903
26
Tropicamide Approved, Investigational Phase 1 1508-75-4 5593
27
Betamethasone Approved, Vet_approved Phase 1 378-44-9 9782
28 Anti-Bacterial Agents Phase 1
29 Lubricant Eye Drops Phase 1
30 Gentamicins Phase 1
31 Insulin, Globin Zinc Phase 1
32 insulin Phase 1
33 Mydriatics Phase 1
34 Antibiotics, Antitubercular Phase 1
35
Verteporfin Approved, Investigational 129497-78-5
36
Prednisolone phosphate Approved, Vet_approved 302-25-0
37
Methylprednisolone Approved, Vet_approved 83-43-2 6741
38
Methylprednisolone hemisuccinate Approved 2921-57-5
39 Prednisolone acetate Approved, Vet_approved 52-21-1
40
Prednisolone Approved, Vet_approved 50-24-8 5755
41
Prednisolone hemisuccinate Experimental 2920-86-7
42 Anecortave Investigational 10184-70-0
43 Photosensitizing Agents
44 Methylprednisolone Acetate
45 Hormones
46 Antineoplastic Agents, Hormonal
47 Hormone Antagonists
48 glucocorticoids
49 Anti-Inflammatory Agents

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Management of Active and Established Corneal Neovascularisation to Prevent Visual Impairment Unknown status NCT02594423 Phase 4 Bevacizumab
2 The Effect of Bevacizumab on Corneal Neovascularization Completed NCT00797303 Phase 4 Bevacizumab
3 Topical Timolol for the Treatment of Benign Vascular Periocular Lesions Withdrawn NCT01250457 Phase 4 topical Timolol
4 Prospective, Double-blind, Randomized, Controlled Clinical Trial of Low Dose Doxycycline in the Treatment of Corneal Burn Unknown status NCT01886560 Phase 2, Phase 3 Doxycycline;Placebo
5 Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization Completed NCT00555594 Phase 2, Phase 3 Bevacizumab (Avastin)
6 Topical/Subconjunctival Injection of Bevacizumab(Avastin) for the Treatment of Corneal Neovascularization Unknown status NCT00992849 Phase 2 Bevacizumab
7 Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose Unknown status NCT02157987 Phase 1, Phase 2 bevacuzimab spray
8 Safety and Efficacy of Topical Pazopanib in Treatment of Corneal Neovascularization Completed NCT01257750 Phase 1, Phase 2 Pazopanib (5mg/ml)
9 Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Completed NCT01072357 Phase 1, Phase 2 Avastin® (bevacizumab);0.9% NaCl & Refresh Liquigel
10 A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Completed NCT01996826 Phase 1, Phase 2 Avastin® (bevacizumab);0.9% NaCl & Refresh Liquigel
11 Clinical Study of Transplantation of Autologous Cultivated Oral Mucosal Epithelial Sheets for Limbal Stem-cell Deficiency Completed NCT02415218 Phase 1, Phase 2
12 Comparative Analysis of Human Amniotic Membrane Graft Versus Contact Lenses in Syntomathic Bullous Keratopathy Completed NCT01926535 Phase 2
13 Investigation of Different Scanning Protocols for 3 Dimensional High-resolution Imaging of the Human Cornea With Optical Coherence Tomography (OCT) - A Pilot Study Recruiting NCT01843101 Phase 2
14 Safety and Feasibility of Cultivated Autologous Limbal Epithelial Cell Transplantation in the Treatment of Limbal Stem Cell Deficiency (LSCD) Recruiting NCT02592330 Phase 1, Phase 2
15 Phase 2 Ziv-aflibercept in Ocular Disease Short and Long-term Study Recruiting NCT02486484 Phase 2 ziv-aflibercept
16 Topical IL-1-Ra for Treatment of Corneal Neovascularization Terminated NCT00915590 Phase 1, Phase 2 Placebo;IL-1Ra
17 The Effect of Subconjunctival Aflibercept on Regression of Corneal Neovascularization Terminated NCT02797704 Phase 1, Phase 2 Aflibercept
18 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
19 The Improvement of Limbal Epithelial Culture Technique for the Treatment of Unilateral Limbal Insufficiency by Using Collagenase to Isolate Limbal Stem Cells Unknown status NCT02202642 Phase 1
20 Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV) Completed NCT00681889 Phase 1 Ranibizumab
21 Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization Completed NCT00559936 Phase 1 Topical Avastin 1%
22 Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery Completed NCT00769145 Phase 1 Ranibizumab
23 Clinical Study: Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries Completed NCT01075347 Phase 1
24 Phase 1 Study of Topical Autologous Insulin Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries Completed NCT01031888 Phase 1 Topical insulin eye drops;Conventional postoperative eye drops
25 An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of Conbercept Eye Drops in Patients With Corneal Neovascularization Recruiting NCT04215393 Phase 1 Conbercept eye drop;Placebo
26 Cultivated Autologous Oral Mucosal Epithelial Transplantation for the Treatment of Ocular Surface Diseases: A Clinical Study Recruiting NCT03943797 Phase 1
27 Subconjunctival Aflibercept Injection for Corneal Neovascularization Terminated NCT01868360 Phase 1 Subconjunctival aflibercept
28 Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Withdrawn NCT02042027 Phase 1 Gamunex-C
29 Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization Completed NCT00512876 Bevacizumab (Avastin)
30 Photodynamic Therapy With Verteporfin for Corneal Neovascularization Completed NCT00471406
31 Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization Completed NCT00004430 Dihematoporphyrin derivative;prednisolone
32 The Application of Subconjunctival Injection of Bevacizumab (Avastin) in the Treatment of Corneal Neovasculization Completed NCT00681603 subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)
33 Clinical Trial Comparing Subconjunctival and Topical Bevacizumab as Adjuncts to Trabeculectomy in Improving Outcomes for Primary Open Angle Glaucoma Completed NCT01425112
34 Neovascularization Patterns in Corneal Graft Rejection Completed NCT01695655
35 Comparison Between Nylon and Polyglactin Corneal Suture in Pediatric Cataract Surgery: a Randomized Controlled Clinical Trial Recruiting NCT03812640
36 Does Specialty Soft Contact Lens Wear Decrease the Onset and Progression of Myopia in Optometry School Interns? Active, not recruiting NCT04334369
37 Clinical Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate Sterile Suspension No longer available NCT00349739 Anecortave Acetate
38 Corneal Thinning During Topical Bevacizumab Therapy Withdrawn NCT00515684 bevacizumab (Avastin)

Search NIH Clinical Center for Corneal Neovascularization

Cochrane evidence based reviews: corneal neovascularization

Genetic Tests for Corneal Neovascularization

Anatomical Context for Corneal Neovascularization

MalaCards organs/tissues related to Corneal Neovascularization:

40
Eye, Endothelial, T Cells, Bone, Neutrophil, Prostate, Lung

Publications for Corneal Neovascularization

Articles related to Corneal Neovascularization:

(show top 50) (show all 1378)
# Title Authors PMID Year
1
A siRNA targeting vascular endothelial growth factor-A inhibiting experimental corneal neovascularization. 61 54
20450250 2010
2
VEGF Trap(R1R2) suppresses experimental corneal angiogenesis. 61 54
19882518 2010
3
Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment. 61 54
19437347 2009
4
Evaluation of cytotoxic effects of bevacizumab on human corneal cells. 61 54
19387236 2009
5
Analysis of angiogenesis induced by cultured corneal and oral mucosal epithelial cell sheets in vitro. 61 54
17904552 2007
6
Inhibition of corneal neovascularization by recombinant adenovirus-mediated sFlk-1 expression. 54 61
17692288 2007
7
Inhibition of corneal neovascularization with a nutrient mixture containing lysine, proline, ascorbic acid, and green tea extract. 61 54
17845900 2007
8
[A synthetic peptide selected by bioinformatics inhibits mouse corneal neovascularization]. 54 61
17459247 2007
9
Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization. 61 54
17198016 2007
10
A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. 54 61
17107753 2007
11
Inhibition of corneal neovascularization by rapamycin. 54 61
16672771 2006
12
Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. 54 61
16195702 2006
13
Proteomic identification of activin receptor-like kinase-1 as a differentially expressed protein during hyaloid vascular system regression. 54 61
16223497 2005
14
Differential conversion of plasminogen to angiostatin by human corneal cell populations. 61 54
16270025 2005
15
Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. 54 61
15851564 2005
16
Corneal neovascularization suppressed by TIMP2 released from human amniotic membranes. 61 54
17162918 2005
17
Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells. 61 54
15326102 2004
18
Suppression of corneal neovascularization by PEDF release from human amniotic membranes. 61 54
15161837 2004
19
Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. 61 54
15126605 2004
20
[Suppression of corneal neovascularization by conditioned culture medium of human amniotic membrane]. 54 61
14769230 2003
21
Thrombospondins 1 and 2 function as inhibitors of angiogenesis. 61 54
12714043 2003
22
VEGF-dependent conjunctivalization of the corneal surface. 61 54
12506063 2003
23
[Expression of vascular endothelial growth factor and its receptors (flt-1) in morbid human corneas and investigation of its clinic importance]. 54 61
15515760 2002
24
Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA. 54 61
12470964 2002
25
Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. 54 61
12122002 2002
26
Suppression of corneal neovascularization by culture supernatant of human amniotic cells. 61 54
11805510 2002
27
HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. 54 61
11118060 2000
28
Towards a closed eye model of the pre-ocular tear layer. 54 61
11029550 2000
29
Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. 54 61
10937562 2000
30
Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. 61 54
10202935 1999
31
Diurnal variations in angiostatin in human tear fluid: a possible role in prevention of corneal neovascularization. 54 61
10342373 1999
32
Inhibition of angiogenesis by interleukin 4. 54 61
9743522 1998
33
The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. 54 61
9733580 1998
34
The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. 61 54
9233641 1997
35
[Inhibition of neovascularization of the eye by dietary factors exemplified by isoflavonoids]. 54 61
9156641 1997
36
Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. 61 54
8988045 1997
37
The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. 54 61
7592998 1995
38
The role of CXC chemokines as regulators of angiogenesis. 61 54
8574748 1995
39
Tecogalan sodium inhibits corneal neovascularization induced by basic fibroblast growth factor. 54 61
8927305 1995
40
Recombinant human epidermal growth factor and corneal neovascularization. 61 54
1289616 1992
41
[Pathophysiology of intraocular neovascularization]. 54 61
1707214 1990
42
Corneal melt in conjunctival intraepithelial neoplasia. 61
32426552 2020
43
FTO regulates ocular angiogenesis via m6A-YTHDF2-dependent mechanism. 61
32531187 2020
44
Early Application of Bevacizumab After Sclerocorneal Grafting for Patients With Severe Late-Stage Ocular Chemical Burns. 61
32040009 2020
45
Inhibition of EZH2 alleviates angiogenesis in a model of corneal neovascularization by blocking FoxO3a-mediated oxidative stress. 61
32562311 2020
46
Development of mucoadhesive cationic polypeptide micelles for sustained cabozantinib release and inhibition of corneal neovascularization. 61
32420566 2020
47
Thermoresponsive gel for sustained release of BMP4 to inhibit corneal neovascularization. 61
32531716 2020
48
Application of Corneal Optical Coherence Tomography Angiography for Assessment of Vessel Depth in Corneal Neovascularization. 61
31868851 2020
49
Comparison of the effect of topical bevacizumab and sorafenib in experimental corneal neovascularization. 61
32338080 2020
50
Analysis of CCR3 expression in corneal neovascularization in a murine model and human corneas. 61
32485201 2020

Variations for Corneal Neovascularization

Expression for Corneal Neovascularization

Search GEO for disease gene expression data for Corneal Neovascularization.

Pathways for Corneal Neovascularization

Pathways related to Corneal Neovascularization according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 TIMP4 TIMP2 SERPINF1 PLG KDR IL1B
2
Show member pathways
13.8 VEGFA TIMP4 TIMP2 TEK KDR IL1B
3
Show member pathways
13.66 VEGFA TIMP4 TIMP2 TEK KDR FLT1
4
Show member pathways
13.51 TIMP4 TIMP2 TEK KDR FLT1 FGF2
5
Show member pathways
13.5 VEGFA TIMP4 TIMP2 TEK KDR IL1B
6
Show member pathways
13.36 VEGFA THBS1 PLG PECAM1 KDR CXCL12
7
Show member pathways
13.32 TIMP4 TIMP2 TEK KDR IL1B FLT1
8
Show member pathways
13.3 TIMP4 TIMP2 TEK KDR FLT1 FGF2
9
Show member pathways
13.27 TIMP4 TIMP2 TEK KDR IL1B FLT1
10
Show member pathways
13.23 VEGFA TIMP4 TIMP2 TEK KDR FLT1
11
Show member pathways
13.03 TIMP4 TIMP2 KDR FLT1 FGF2 CXCL12
12
Show member pathways
13.03 TIMP4 TIMP2 KDR FLT1 FGF2 DDR2
13
Show member pathways
12.95 VEGFA THBS1 TEK KDR FLT1 FGF2
14 12.74 VEGFA TEK KDR IL1B FLT1 FGF2
15
Show member pathways
12.71 VEGFA THBS1 TEK KDR FLT1 FGF2
16
Show member pathways
12.69 TIMP2 THBS1 PLG PECAM1 KDR FGF2
17
Show member pathways
12.62 TIMP4 TIMP2 KDR IL1B FLT1 FGF2
18
Show member pathways
12.45 VEGFA KDR FLT1 FGF2
19
Show member pathways
12.34 VEGFA KDR FLT1 FGF2
20 12.26 VEGFA THBS1 KDR FGF2
21
Show member pathways
12.16 TIMP4 TIMP2 TEK KDR FLT1 FGF2
22 12.13 TEK KDR FLT1 FGF2 DDR2
23
Show member pathways
12.08 TIMP4 TIMP2 KDR IL1B FLT1 FGF2
24 12.07 VEGFA PECAM1 KDR IL1B
25
Show member pathways
11.85 TIMP4 TIMP2 PLG
26
Show member pathways
11.81 VEGFA KDR FLT1
27 11.77 VEGFA TEK IL1B FLT1 CXCL12
28 11.64 VEGFA FGF2 DDR2
29 11.53 VEGFA PLG KDR FGF2
30 11.51 THBS1 PECAM1 IL1B
31 11.47 VEGFA KDR FGF2
32 11.45 TIMP2 THBS1 TEK PECAM1 KDR FLT1
33 11.44 VEGFA KDR FLT1 FGF2
34 11.32 VEGFA KDR FLT1
35 11.23 THBS1 PLG FGF2 CXCL12
36 11.08 VEGFA SLIT2 FLT1 FGF2
37
Show member pathways
10.96 VEGFA KDR FLT1
38 10.78 PLG HRG
39 10.76 TIMP4 TIMP2 TEK KDR IL1B FLT1
40 10.48 VEGFA TIMP2 TEK KDR FLT1 FGF2

GO Terms for Corneal Neovascularization

Cellular components related to Corneal Neovascularization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.8 VEGFA TIMP2 THBS1 TEK PLG HRG
2 extracellular space GO:0005615 9.77 VEGFA TIMP4 TIMP2 THBS1 SLIT2 SERPINF1
3 collagen-containing extracellular matrix GO:0062023 9.73 TIMP2 THBS1 SERPINF1 PLG HRG CXCL12
4 extracellular matrix GO:0031012 9.71 VEGFA TIMP4 TIMP2 THBS1
5 receptor complex GO:0043235 9.67 TEK KDR FLT1 DDR2
6 extracellular region GO:0005576 9.5 VEGFA TIMP4 TIMP2 THBS1 TEK SLIT2
7 platelet alpha granule lumen GO:0031093 9.46 VEGFA THBS1 PLG HRG

Biological processes related to Corneal Neovascularization according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.21 VEGFA TEK SLIT2 ROBO4 KDR FLT1
2 negative regulation of apoptotic process GO:0043066 10.1 VEGFA THBS1 TEK KDR CRYAA
3 extracellular matrix organization GO:0030198 10 THBS1 PECAM1 KDR FGF2 DDR2
4 protein autophosphorylation GO:0046777 9.97 TEK KDR FLT1 DDR2
5 response to hypoxia GO:0001666 9.97 VEGFA THBS1 TEK CXCL12
6 positive regulation of protein phosphorylation GO:0001934 9.97 VEGFA TEK PECAM1 KDR IL1B
7 positive regulation of cell proliferation GO:0008284 9.97 VEGFA THBS1 KDR IL1B FLT1 FGF2
8 negative regulation of endopeptidase activity GO:0010951 9.94 TIMP4 TIMP2 SERPINF1 HRG
9 peptidyl-tyrosine phosphorylation GO:0018108 9.94 TEK KDR FLT1 DDR2
10 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.93 TEK KDR FLT1 DDR2
11 negative regulation of angiogenesis GO:0016525 9.91 THBS1 TEK SERPINF1 HRG CXCL10
12 platelet degranulation GO:0002576 9.89 VEGFA THBS1 PLG PECAM1 HRG
13 response to organic substance GO:0010033 9.88 TIMP4 TIMP2 TEK
14 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.88 TEK KDR FLT1
15 positive regulation of kinase activity GO:0033674 9.88 TEK KDR FLT1 DDR2
16 positive regulation of MAPK cascade GO:0043410 9.88 TIMP2 TEK KDR FLT1 FGF2
17 chemotaxis GO:0006935 9.88 SLIT2 HRG FLT1 FGF2 CXCL12 CXCL10
18 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.86 VEGFA KDR FLT1
19 positive regulation of MAP kinase activity GO:0043406 9.86 VEGFA FLT1 FGF2
20 response to peptide hormone GO:0043434 9.85 TIMP4 TEK CXCL12
21 positive regulation of endothelial cell migration GO:0010595 9.85 VEGFA THBS1 TEK KDR
22 positive chemotaxis GO:0050918 9.84 VEGFA FGF2 CXCL10
23 positive regulation of cell division GO:0051781 9.83 VEGFA IL1B FGF2
24 positive regulation of blood vessel endothelial cell migration GO:0043536 9.83 VEGFA THBS1 KDR FGF2
25 positive regulation of endothelial cell proliferation GO:0001938 9.83 VEGFA TEK KDR FGF2 CXCL12
26 negative regulation of blood vessel endothelial cell migration GO:0043537 9.82 THBS1 HRG FGF2
27 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.81 VEGFA KDR FGF2
28 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.79 VEGFA KDR FLT1
29 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.79 TEK FLT1 FGF2
30 negative regulation of endothelial cell migration GO:0010596 9.77 THBS1 SLIT2 SERPINF1
31 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.76 VEGFA IL1B FLT1
32 positive regulation of focal adhesion assembly GO:0051894 9.76 VEGFA TEK KDR HRG
33 vascular endothelial growth factor signaling pathway GO:0038084 9.73 VEGFA KDR FLT1
34 induction of positive chemotaxis GO:0050930 9.71 VEGFA CXCL12
35 positive regulation of fibroblast migration GO:0010763 9.71 THBS1 DDR2
36 negative regulation of fibrinolysis GO:0051918 9.71 THBS1 PLG HRG
37 positive regulation of phospholipase C activity GO:0010863 9.7 FLT1 FGF2
38 positive regulation of positive chemotaxis GO:0050927 9.7 VEGFA KDR
39 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.7 VEGFA PLG
40 positive regulation of angiogenesis GO:0045766 9.7 VEGFA THBS1 TEK KDR IL1B FLT1
41 ovulation cycle GO:0042698 9.69 TIMP4 SERPINF1
42 vascular wound healing GO:0061042 9.69 VEGFA KDR
43 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.69 TIMP4 TIMP2
44 positive regulation of axon extension involved in axon guidance GO:0048842 9.68 VEGFA CXCL12
45 negative regulation of lamellipodium assembly GO:0010593 9.67 SLIT2 HRG
46 cell migration involved in sprouting angiogenesis GO:0002042 9.67 VEGFA SLIT2 KDR FGF2
47 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.66 VEGFA KDR
48 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.65 VEGFA KDR
49 sprouting angiogenesis GO:0002040 9.65 VEGFA THBS1 TEK KDR FLT1
50 negative regulation of endothelial cell chemotaxis GO:2001027 9.62 THBS1 HRG

Molecular functions related to Corneal Neovascularization according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.3 VEGFA TIMP4 TIMP2 THBS1 TEK SLIT2
2 identical protein binding GO:0042802 10.04 VEGFA THBS1 TEK SLIT2 KDR FGF2
3 protein tyrosine kinase activity GO:0004713 9.67 TEK KDR FLT1 DDR2
4 cytokine activity GO:0005125 9.65 VEGFA IL1B FGF2 CXCL12 CXCL10
5 growth factor binding GO:0019838 9.61 TEK KDR FLT1
6 chemoattractant activity GO:0042056 9.58 VEGFA FGF2 CXCL10
7 CXCR chemokine receptor binding GO:0045236 9.52 CXCL12 CXCL10
8 proteoglycan binding GO:0043394 9.51 THBS1 SLIT2
9 vascular endothelial growth factor binding GO:0038085 9.48 KDR FLT1
10 vascular endothelial growth factor-activated receptor activity GO:0005021 9.46 KDR FLT1
11 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.46 TEK KDR FLT1 DDR2
12 heparin binding GO:0008201 9.43 VEGFA THBS1 SLIT2 HRG FGF2 CXCL10
13 integrin binding GO:0005178 9.1 TIMP2 THBS1 KDR IL1B FGF2 CXCL12

Sources for Corneal Neovascularization

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....